Eculizumab is a recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Eculizumab is a monoclonal antibody that targets complement protein C5.
- Mechanism
- Curator reviewed · 6 references
Eculizumab is a monoclonal antibody that targets complement protein C5, preventing cleavage to C5a and C5b, and the formation of the terminal complement complex C5b-9. Inhibition of this complex prevents complement mediated intravascular hemolysis in paroxysmal nocturnal hemoglobunuria, complement mediated microangiopathy in atypical hemolytic uremic syndrome, and immune mediated inflammation and damage of the central nervous system in neuromyelitis optica spectrum disorder.
- Primary indication
- Eculizumab is indicated in the US to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy, and neuromyelitis optica spectrum disorder (NMOSD).Curator reviewed · 5 structured indications
- Formula / weight
- 148000.0 Da
- First approval
- Canada, 2013 · United States, 2007 · European Union, 2016
- Code names
- 5G1.1 · H5G1-1
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Eculizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account